signature=a1db436b83ed565a087e55172ccbf754,Form 8-K/A
0001193125-20-267232.txt : 20201009
0001193125-20-267232.hdr.sgml : 20201009
20201009162302
ACCESSION NUMBER:0001193125-20-267232
CONFORMED SUBMISSION TYPE:8-K/A
PUBLIC DOCUMENT COUNT:14
CONFORMED PERIOD OF REPORT:20201006
ITEM INFORMATION:Financial Statements and Exhibits
FILED AS OF DATE:20201009
DATE AS OF CHANGE:20201009
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME:NN INC
CENTRAL INDEX KEY:0000918541
STANDARD INDUSTRIAL CLASSIFICATION:BALL & ROLLER BEARINGS [3562]
IRS NUMBER:621096725
STATE OF INCORPORATION:DE
FISCAL YEAR END:1231
FILING VALUES:
FORM TYPE:8-K/A
SEC ACT:1934 Act
SEC FILE NUMBER:001-39268
FILM NUMBER:201233418
BUSINESS ADDRESS:
STREET 1:207 MOCKINGBIRD LANE
CITY:JOHNSON CITY
STATE:TN
ZIP:37604
BUSINESS PHONE:423-434-8300
MAIL ADDRESS:
STREET 1:207 MOCKINGBIRD LANE
CITY:JOHNSON CITY
STATE:TN
ZIP:37604
FORMER COMPANY:
FORMER CONFORMED NAME:NN BALL & ROLLER INC
DATE OF NAME CHANGE:19940203
8-K/A
1
d948551d8ka.htm
FORM 8-K/A
Form 8-K/A
NN INC true 0000918541 0000918541 2020-10-06 2020-10-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 9, 2020 (October 6, 2020)
NN, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-23486
62-1096725
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
6210 Ardrey Kell Road
Charlotte, North Carolina
28277
(Address of principal executive offices)
(Zip Code)
(980) 264-4300
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
symbol
Name of each exchange
on which registered
Common Stock, par value $0.01
NNBR
The Nasdaq Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act:
None
(Title of class)
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company. ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
This Amendment corrects certain typographical errors as well as errors in the calculation of certain Life Sciences Business Adjustments appearing in the unaudited pro forma condensed consolidated balance sheet of NN, Inc. (“NN”) as of June 30, 2020 and the unaudited pro forma condensed consolidated statements of operations of NN for the years ended December 31, 2017, December 31, 2018 and December 31, 2019 and the six months ended June 30, 2020, which were filed as Exhibit 99.2 to the Form 8-K filed with the Securities and Exchange Commission on October 8, 2020.
ITEM 9.01.
FINANCIAL STATEMENTS AND EXHIBITS.
(b) Pro Forma Financial Information
NN’s unaudited pro forma condensed consolidated balance sheet as of June 30, 2020, and the unaudited pro forma condensed consolidated statements of operations for the years ended December 31, 2017, December 31, 2018 and December 31, 2019 and the six months ended June 30, 2020, and the notes related thereto, which have been updated to correct the errors noted above, are filed as Exhibit 99.1 and are hereby incorporated herein by reference.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 9, 2020
NN, INC.
By:
/s/ Matthew S. Heiter
Name:
Matthew S. Heiter
Title:
Senior Vice President, General Counsel
EX-99.1
2
d948551dex991.htm
EX-99.1
EX-99.1
Exhibit 99.1
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION
On October 6, 2020, NN, Inc. (the Company) completed the sale of its life sciences business (the Life Sciences
Business) to ASP Navigate Acquisition Corp. for total cash consideration of approximately $757.2 million. An additional earnout payment of up to $70 million may be payable to the Company during the year ending December 31, 2023,
if certain performance measures are achieved by the Life Sciences Business through December 31, 2022.
The unaudited pro forma
condensed consolidated balance sheet and the unaudited pro forma condensed consolidated statements of operations are derived from, and should be read in conjunction with, the historical financial statements and notes thereto of the Company, as
presented in its Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (SEC) on March 16, 2020, and its Quarterly Report on
Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on August 7, 2020.
The unaudited pro forma condensed consolidated financial statements have been prepared giving effect to the sale of the Companys Life
Sciences Business (the Transaction) as if the Transaction had occurred on June 30, 2020, for the unaudited pro forma condensed consolidated balance sheet and on January 1, 2017, for the unaudited pro forma condensed
consolidated statements of operations. The unaudited pro forma condensed consolidated financial statements have been prepared giving effect to the required use of proceeds to prepay a portion of the Companys credit facilities with all of the
net proceeds from the Transaction as if the prepayment of credit facilities had occurred on June 30, 2020, for the unaudited pro forma condensed consolidated balance sheet and on January 1, 2017, for the unaudited pro forma condensed
consolidated statements of operations.
The unaudited pro forma condensed consolidated financial statements are prepared in accordance
with Article 11 of Regulation S-X. The pro forma adjustments are described in the accompanying notes and are based upon information and assumptions available at the time of the filing of this Current Report on
Form 8-K.
The unaudited pro forma condensed financial statements do not purport to represent and
are not necessarily indicative of what the Companys actual financial position and results of operations would have been had the transaction occurred on the dates indicated. In addition, these unaudited pro forma condensed consolidated
financial statements should not be considered to be indicative of the Companys future financial performance.
The unaudited pro
forma condensed consolidated financial information includes information, statements, and assumptions that are or may be considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements generally may be identified by the use of words such as may, should, will, expect, anticipate, continue, estimate, project,
believe, plan or similar expressions. Statements that describe objectives, plans, or goals also are forward-looking statements. These forward-looking statements involve risks and uncertainties, and actual results may differ
materially from those contemplated by the forward-looking statements due to, among other, the risks and uncertainties described under the heading Risk Factors in the Companys Annual Report on Form
10-K for the fiscal year ended December 31, 2019, and in the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. For any
forward-looking statements contained herein, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and the Company undertakes no obligation to update
publicly or revise any forward-looking statements in light of the new information or future events, except as required by law.
1
Unaudited Pro Forma Condensed Consolidated Balance Sheet
As of June 30, 2020
(in thousands)
Consolidated
Historical
NN, Inc.
Life
Sciences
Business
Adjustments
Other
Pro Forma
Adjustments
Notes
Pro
Forma
Assets
Current assets:
Cash and cash equivalents
$
82,695
$
(12,158
)
$
14,289
(h
)
$
84,826
Accounts receivable, net
105,661
(37,370
)
68,291
Inventories
121,031
(51,950
)
69,081
Income tax receivable
17,458
17,458
Other current assets
15,477
(4,087
)
11,390
Total current assets
342,322
(105,565
)
14,289
251,046
Property, plant and equipment, net
344,073
(116,050
)
228,023
Operating lease
right-of-use assets
77,121
(24,825
)
52,296
Goodwill
196,467
(196,467
)
Intangible assets, net
306,577
(196,338
)
110,239
Investment in joint venture
22,104
22,104
Other non-current assets
7,350
(290
)
7,060
Total assets
$
1,296,014
$
(639,535
)
$
14,289
$
670,768
Liabilities, Preferred Stock, and Stockholders Equity
Current liabilities:
Accounts payable
$
43,751
$
(12,010
)
$
$
31,741
Accrued salaries, wages and benefits
33,335
(15,925
)
17,410
Income tax payable
867
(267
)
600
Current maturities of long-term debt
20,567
(219
)
20,348
Current portion of operating lease liabilities
7,068
(2,618
)
4,450
Other current liabilities
32,266
(5,961
)
26,305
Total current liabilities
137,854
(37,000
)
100,854
Deferred tax liabilities
73,691
(56,821
)
(b
)
16,870
Long-term debt, net of current portion
816,956
(884
)
(687,493
)
(a
)
128,579
Operating lease liabilities, net of current portion
79,712
(22,912
)
56,800
Other non-current liabilities
31,195
(4,983
)
26,212
Total liabilities
1,139,408
(65,779
)
(744,314
)
329,315
Series B convertible preferred stock
98,707
98,707
Total stockholders equity
57,899
(573,756
)
758,603
(d
)
242,746
Total liabilities, preferred stock, and stockholders equity
$
1,296,014
$
(639,535
)
$
14,289
$
670,768
See accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.
2
Unaudited Pro Forma Condensed Consolidated Statement of Operations
For the Six Months Ended June 30, 2020
(in thousands, except per share data)
Consolidated
Historical
NN, Inc.
Life Sciences
Business
Adjustments
Other
Pro Forma
Adjustments
Notes
Pro Forma
Net sales
$
350,165
(156,447
)
$
193,718
Cost of sales (exclusive of depreciation and amortization shown separately below)
267,630
(109,121
)
158,509
Selling, general and administrative expense
45,815
(14,024
)
(1,358
)
(c
)
30,433
Depreciation and amortization
46,385
(23,701
)
22,684
Goodwill impairment
239,699
(146,757
)
92,942
Other operating expense, net
4,174
3
4,177
Income (loss) from operations
(253,538
)
137,153
1,358
(115,027
)
Interest expense
35,773
345
(25,192
)
(e
)
10,926
Other expense, net
239
259
498
Income (loss) before benefit for income taxes
(289,550
)
136,549
26,550
(126,451
)
Benefit (provision) for income taxes
18,955
6,363
(5,575
)
(f
)
19,743
Share of net income from joint venture
656
656
Loss from continuing operations
$
(269,939
)
$
142,912
$
20,975
$
(106,052
)
Basic net loss per common share:
Loss from continuing operations per common share
$
(6.55
)
$
(2.66
)
Weighted average shares outstanding
42,154
42,154
Diluted net loss per common share:
Loss from continuing operations per common share
$
(6.55
)
$
(2.66
)
Weighted average shares outstanding
42,154
42,154
See accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.
3
Unaudited Pro Forma Condensed Consolidated Statement of Operations
For the Year Ended December 31, 2019
(in thousands, except per share data)
Consolidated
Historical
NN, Inc.
Life Sciences
Business
Adjustments
Other
Pro Forma
Adjustments
Notes
Pro
Forma
Net sales
$
847,451
(359,732
)
$
487,719
Cost of sales (exclusive of depreciation and amortization shown separately below)
641,639
(250,952
)
390,687
Selling, general and administrative expense
103,223
(34,330
)
68,893
Depreciation and amortization
91,846
(46,950
)
44,896
Restructuring and integration expense, net
(12
)
(12
)
Other operating expense (income), net
866
(20
)
846
Income (loss) from operations
9,889
(27,480
)
(17,591
)
Interest expense
57,155
498
(46,935
)
(e
)
10,718
Loss on extinguishment of debt and write-off of debt
issuance costs
3,293
(2,741
)
(g
)
552
Other expense (income), net
1,140
(178
)
962
Loss before benefit for income taxes
(51,699
)
(27,800
)
49,676
(29,823
)
Benefit (provision) for income taxes
3,277
7,728
(10,432
)
(f
)
573
Share of net income from joint venture
1,681
1,681
Loss from continuing operations
$
(46,741
)
$
(20,072
)
$
39,244
$
(27,569
)
Basic net loss per common share:
Loss from continuing operations per common share
$
(1.13
)
$
(0.67
)
Weighted average shares outstanding
42,030
42,030
Diluted net loss per common share:
Loss from continuing operations per common share
$
(1.13
)
$
(0.67
)
Weighted average shares outstanding
42,030
42,030
See accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.
4
Unaudited Pro Forma Condensed Consolidated Statement of Operations
For the Year Ended December 31, 2018
(in thousands, except per share data)
Consolidated
Historical
NN, Inc.
Life Sciences
Business
Adjustments
Other
Pro Forma
Adjustments
Notes
Pro Forma
Net sales
$
770,657
(248,173
)
$
522,484
Cost of sales (exclusive of depreciation and amortization shown separately below)
589,181
(177,497
)
411,684
Selling, general and administrative expense
93,583
(20,927
)
72,656
Acquisition related costs excluded from selling, general and administrative expense
5,871
(5,763
)
108
Depreciation and amortization
71,128
(28,102
)
43,026
Goodwill impairment
182,542
182,542
Restructuring and integration expense, net
2,127
(1,438
)
689
Other operating expense, net
6,089
737
6,826
Loss from operations
(179,864
)
(15,183
)
(195,047
)
Interest expense
61,243
49
(52,671
)
(e)
8,621
Loss on extinguishment of debt and write-off of debt
issuance costs
19,562
(19,562
)
(g)
Other expense (income), net
1,341
675
2,016
Loss before benefit for income taxes
(262,010
)
(15,907
)
72,233
(205,684
)
Benefit (provision) for income taxes
13,413
3,802
(15,169
)
(f)
2,046
Share of net loss from joint venture
(14,390
)
(14,390
)
Loss from continuing operations
$
(262,987
)
$
(12,105
)
$
57,064
$
(218,028
)
Basic net loss per common share:
Loss from continuing operations per common share
$
(8.30
)
$
(6.88
)
Weighted average shares outstanding
31,678
31,678
Diluted net loss per common share:
Loss from continuing operations per common share
$
(8.30
)
$
(6.88
)
Weighted average shares outstanding
31,678
31,678
See accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.
5
Unaudited Pro Forma Condensed Consolidated Statement of Operations
For the Year Ended December 31, 2017
(in thousands, except per share data)
Consolidated
Historical
NN, Inc.
Life Sciences
Business
Adjustments
Other
Pro Forma
Adjustments
Notes
Pro
Forma
Net sales
$
619,793
(98,329
)
$
521,464
Cost of sales (exclusive of depreciation and amortization shown separately below)
460,414
(64,949
)
395,465
Selling, general and administrative expense
74,112
(8,504
)
65,608
Acquisition related costs excluded from selling, general and administrative expense
344
344
Depreciation and amortization
52,406
(12,091
)
40,315
Restructuring and integration expense, net
386
386
Other operating expense, net
351
351
Income (loss) from operations
31,780
(12,785
)
18,995
Interest expense
52,085
52
(24,737
)
(e
)
27,400
Loss on extinguishment of debt and write-off of debt
issuance costs
42,087
(